SCImago Journal & Country Rank
This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE)
2020, Volume 36, Number 2, Page(s) 154-158     
[ Full Text ] [ PDF ] [ Similar Articles ]
DOI: 10.5146/tjpath.2020.01478
Long-Term Effects of Tenofovir on Liver Histopathology in Patients with Chronic Viral Hepatitis B Infection
Bengü TATAR1, Selma GÜL2, Şükran KÖSE1, Emel PALA3
1Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences ,Izmir Tepecik Education and Research Hospital, IZMIR, TURKEY
2Batman State Hospital, BATMAN, TURKEY
3Department of Pathology, University of Health Sciences, Izmir Tepecik Education and Research Hospital, IZMIR, TURKEY
Keywords: Tenofovir, Hepatitis B, Histopathology

Objective: The aim of this study to evaluate histopathological improvement and virological, serological and biochemical response rates in patients with chronic hepatitis B (CHB) who were treated with tenofovir disoproxil fumarate (TDF).

Material and Method: A total of 91 nucleosid(t)e-naive CHB patients who received TDF were evaluated. Virological, serological and biochemical test results were assessed at baseline and every 12 weeks. Liver biopsy specimens were assessed according to the modified Ishak scoring.

Results: The study was conducted on 52 patients. The mean age was 40±10 years and 40.4% were female. The mean follow-up period was 33±11 months. HBsAg seroclearance occurred in none of the patients. The serum level of HBV-DNA became undetectable in 94.2% of the patients. Mean histological activity index at baseline and on-treatment were 8.2±2.3 and 6.2±2.0 and the mean fibrosis scores were 2.65±1.3 and 2.33±1.1, respectively.

Conclusion: We determined that TDF therapy provided remarkably good HBV DNA suppression and biochemical response rates, but low seroconversion. Improvement of liver necroinflammation was detected, but no significant change observed in fibrosis.

[ Full Text ] [ PDF ] [ Similar Articles ]